Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could 3 radiation doses beat 4 for cervical cancer?

NCT ID NCT07022470

First seen Jun 16, 2026 · Last updated Jun 22, 2026 · Updated 1 time

Summary

This study compares a shorter course of brachytherapy (3 sessions) to the standard 4-session regimen for locally advanced cervical cancer. About 41 participants will receive either 3 or 4 high-dose radiation treatments based on what is feasible for them. The goal is to see if the shorter schedule is practical and still controls the disease effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radiation (brachytherapy)

What this could lead to

If successful, this could show that fewer radiation sessions are enough to control cervical cancer, making treatment shorter and more convenient.

What could go wrong

This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. The 3-fraction schedule might not control the cancer as well as the standard 4-fraction regimen.

Conditions

The condition(s) this trial relates to.

Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.